Morpho-Functional 1H-MRI of the Lung in COPD: Short-Term Test-Retest Reliability by Jobst, Bertram J. et al.
RESEARCH ARTICLE
Morpho-Functional 1H-MRI of the Lung in
COPD: Short-Term Test-Retest Reliability
Bertram J. Jobst1,2,3*, Mark O. Wielpütz1,2,3, Simon M. F. Triphan1,2,4, Angela Anjorin1,2,3,
Julia Ley-Zaporozhan1,2,5, Hans-Ulrich Kauczor1,2,3, Jürgen Biederer1,2,6,
Sebastian Ley1,2,7, Oliver Sedlaczek1,2,3
1 Department of Diagnostic & Interventional Radiology, University Hospital of Heidelberg, Heidelberg,
Germany, 2 Translational Lung Research Center Heidelberg (TLRC), Member of the German Lung
Research Center (DZL), Heidelberg, Germany, 3 Department of Diagnostic and Interventional Radiology
with Nuclear Medicine, Thoraxklinik at University of Heidelberg, Heidelberg, Germany, 4 Research Center
Magnetic Resonance Bavaria (MRB), Würzburg, Germany, 5 Institute for Clinical Radiology, Ludwig-
Maximilians-University Hospital Munich, Munich, Germany, 6 Radiologie Darmstadt, Department of
Radiology, County Hospital Gross-Gerau, Gross-Gerau, Germany, 7 Department of Diagnostic &




Non-invasive end-points for interventional trials and tailored treatment regimes in chronic
obstructive pulmonary disease (COPD) for monitoring regionally different manifestations of
lung disease instead of global assessment of lung function with spirometry would be valuable.
Proton nuclear magnetic resonance imaging (1H-MRI) allows for a radiation-free assessment
of regional structure and function. The aim of this study was to evaluate the short-term repro-
ducibility of a comprehensive morpho-functional lung MRI protocol in COPD.
Materials and Methods
20 prospectively enrolled COPD patients (GOLD I-IV) underwent 1H-MRI of the lung at 1.5T
on two consecutive days, including sequences for morphology, 4D contrast-enhanced perfu-
sion, and respiratory mechanics. Image quality and COPD-related morphological and func-
tional changes were evaluated in consensus by three chest radiologists using a dedicated
MRI-based visual scoring system. Test-retest reliability was calculated per each individual
lung lobe for the extent of large airway (bronchiectasis, wall thickening, mucus plugging) and
small airway abnormalities (tree in bud, peripheral bronchiectasis, mucus plugging), consoli-
dations, nodules, parenchymal defects and perfusion defects. The presence of tracheal nar-
rowing, dystelectasis, pleural effusion, pulmonary trunk ectasia, right ventricular enlargement
and, finally, motion patterns of diaphragma and chest wall were addressed.
Results
Median global scores [10(Q1:8.00;Q3:16.00) vs.11(Q1:6.00;Q3:15.00)] as well as category
subscores were similar between both timepoints, and kappa statistics indicated “almost
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perfect” global agreement (ĸ = 0.86, 95%CI = 0.81–0.91). Most subscores showed at least
“substantial” agreement of MRI1 and MRI2 (ĸ = 0.64–1.00), whereas the agreement for the
diagnosis of dystelectasis/effusion (ĸ = 0.42, 95%CI = 0.00–0.93) was “moderate” and of
tracheal abnormalities (ĸ = 0.21, 95%CI = 0.00–0.75) “fair”. Most MRI acquisitions showed
at least diagnostic quality at MRI1 (276 of 278) and MRI2 (259 of 264).
Conclusion
Morpho-functional 1H-MRI can be obtained with reproducible image quality and high short-
term test-retest reliability for COPD-related morphological and functional changes of the
lung. This underlines its potential value for the monitoring of regional lung characteristics in
COPD trials.
Introduction
At present, pulmonary function testing is the method of choice for initial diagnosis and follow-
up of chronic obstructive pulmonary disease [1]. As manifestations of the disease are typically
inhomogeneous with different degrees of involvement throughout the lung and as compensa-
tion of functional impairment of the diseased areas by intact portions of the organ is relevant,
global parameters from PFT such as FEV1% may not be optimally suitable for monitoring dis-
ease activity and the efficacy of treatment [1]. Due to the evolving spectrum of therapeutic
options for COPD patients, requirements related to the monitoring of lung structure and func-
tion in interventional COPD trials are increased. Alternative endpoints which reflect changes
in regional lung structure and function would be most welcome. Many requirements in this
field are met by computed tomography (CT), which is the current modality of choice for in
vivo imaging of COPD [2], but longitudinal follow-up with CT cannot be achieved without
excess radiation exposure [3]. In recent years proton MRI has emerged as a promising new
option for the radiation-free characterization and follow-up of COPD [4–6]. Current MRI
techniques comprise morphological as well as functional sequences combining reasonable
diagnostic accuracy with relatively easy handling [7]. In this context, MRI-based monitoring of
patients with cystic fibrosis demonstrated the ability of MRI to depict alterations of lung struc-
ture and perfusion, and detect the response to therapy in patients with exacerbation [8]. MRI
perfusion imaging has already been shown to be able to distinguish patients with mild COPD
from healthy controls [9], and to correlate well with both FEV1% [10] and diffusing capacity
[11]. But the applicability of imaging procedures in the context of patient monitoring not only
depends on diagnostic accuracy and easy handling, but also on reproducibility. Test-retest reli-
ability of imaging-derived biomarkers such as scores for morphologic changes and perfusion
needs to be assessed before their use as trial endpoints in the scientific or clinical context. The
aim of this study was to shape a streamlined MRI protocol based on commercially (“out of the
box”) available sequences which provides a comprehensive assessment of both morphological
and functional lung characteristics of COPD patients within a single study and evaluate its
short-term test-retest reliability. For this purpose, 20 COPD patients of different GOLD stages
underwent MRI on two consecutive days, and all exams were assessed using an established
MRI score for airways disease.
Test-Retest Reliability of Lung MRI in COPD
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Methods
Ethics statement
This prospective study was approved by the Institutional Review Board of the Medical Faculty
of the University of Heidelberg, Germany. The work was carried out in accordance with the
Declaration of Helsinki (The Code of Ethics of the World Medical Association). Prior to partic-
ipation in the study, all subjects gave their written informed consent.
Study design and patient characteristics
N = 20 patients [median age 66 (Q1:59; Q3:74) years] diagnosed with COPD and different dis-
ease severity according to the GOLD criteria [12] were enrolled. The cohort included n = 10
patients with mild COPD (GOLD stages I-II) recruited from an outpatient clinic, and n = 10
patients with severe COPD (GOLD stages III-IV) from a specialized chest clinic (Table 1).
Each patient prospectively underwent an identical lung MRI exam on two consecutive days
(MRI1 / MRI2).
Imaging
The MRI protocol was specifically tailored to the demands of structural and functional alter-
ations of the pulmonary parenchyma, vasculature and airways using a clinical 1.5T scanner
(Magnetom Avanto, Siemens Medical Solutions, Erlangen, Germany) and current protocol
recommendations based on commercially available sequences [7]. Structural aspects were
addressed with the following sequences in coronal and transverse orientation: Volume inter-
polated gradient echo (GRE, VIBE), acquired in inspiratory breath-holds, before and after
contrast application (incl. fat saturation), fat-saturated, free-breathing periodically rotated
overlapping parallel lines with enhanced reconstruction (BLADE), acquired in free breathing
and triggered to the expiratory phase, half-fourier acquisition single-shot turbo spin-echo
(HASTE) in inspiratory breath-holds, and balanced steady-state free precession (bSSFP, True-
FISP) during free breathing. Breath-holding times of most morphological sequences were kept
below 25 seconds, except VIBEs that include fat saturation pulses. Dynamic contrast enhanced
(DCE) first pass perfusion MRI was based on a three-dimensional GRE view sharing sequence
with stochastic trajectories (TWIST) at high temporal resolution (1.47 s/volume) during inspi-
ratory breath-hold and contrast bolus injection by a power injector (0.05 mmol/kg Gd-DTPA,
Magnevist, Bayer Schering Pharma AG, Berlin, German) at a rate of 5 ml/s followed by a bolus
chaser of 30 ml NaCl). The acquisition comprised 24 consecutive measurements, covering a
time span of max. 37s. The initial passage of the contrast bolus through the pulmonary vascula-
ture required a breath-holding time of 15–25 seconds. Patients were advised to hold breath as
long as possible and then breathe shallowly. Subtraction images in coronal orientation with a
spatial resolution of 1.95 x 1.95 mm in-plane and 5 mm slice thickness were used for visual
Table 1. Patient characteristics. 10 patients with mild COPD (GOLD stages I & II) and 10 patients with
severe COPD (GOLD stages III & IV) were enrolled into the study.
GOLD I & II GOLD III & IV Global
N 10 10 20
Male / Female (n) 9/1 9/1 18/2
Min age (y) 49 60 49
Max age (y) 77 79 79
Median age (y) 59 (Q1:55; Q3:70) 69 (Q1:63; Q3:74) 66 (Q1:59; Q3:74)
doi:10.1371/journal.pone.0137282.t001
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analysis. For the evaluation of respiratory mechanics, two-dimensional time-resolved TrueFISP
(dynamic TrueFISP) sequences were acquired during maximum inspiration and expiration in
coronal and angulated sagittal orientation, each through the center of the right and left dia-
phragm. In total, image acquisition took on average 30 minutes. Details on the applied
sequence parameters are provided in Table 2.
Image evaluation
MRI1 and MRI2 were evaluated employing a scoring system specifically reporting the extent
and distribution of COPD-related abnormalities, which was a modification of a previously
established MRI scoring system for airways disease [8,13]. The scoring system categorizes
COPD-related abnormalities, and each category is rated with a 3-point scale of 0, 1 or 2 or a
2-point scale of 0 and 1 (max. score 98) in a lobe-based approach as described in the following:
Tracheal disease. For the diagnosis of tracheal disease, we considered conditions affecting
the structure of the trachea or right and left stem bronchi such as collapse, stenosis, or saber
sheath trachea. The rating of tracheal pathologies was mainly based on inspiratory VIBE,
BLADE, and TrueFISP. The BLADE images were acquired during expiratory phase and thus
provided complementary information to inspiratory VIBE images. Together, the previously
mentioned sequences allowed for the visual evaluation of the tracheal cross-sectional area dur-
ing the breathing cycle: 0 = absent, 1 = moderate ( 50% decrease in lumen area), 2 = severe
(> 50% decrease in lumen area).
Bronchial disease. This category summarizes COPD-related pathologies with localisation
in the lobar bronchi and segmental bronchi in a combined approach [13], i.e. bronchiectasis,
bronchial wall thickening, stenosis, and bronchial mucus plugging with hyperintense intralum-
inal appearance on T2-weighted images. 0 = absent, 1 =50% of lobe, 2 =>50% of lobe.

















TrueFISP 2D cor free native 339.29 1.16 500×500 4.0 19.5×1.95 256×256 0:43
TrueFISP 2D tra free native 290.30 1.16 440×358 4.0 1.95×1.95 256×208 0:37
VIBE 3D cor insp native 3.20 1.14 500×500 4.0 0.98×0.98 256×256 0:20
VIBE 3D tra insp native 3.46 1.18 400×350 4.0 1.56×1.56 256×224 0:23
HASTE 2D cor insp native 600 32.00 500×500 6.0 0.98×0.98 512×512 0:13×2
HASTE 2D tra insp native 571 42.00 400×350 6.0 1.56×1.56 256×224 0:18
BLADE 2D cor trig native 6300.25 83.00 500×500 4.0 1.56×1.56 320×320 2:49
BLADE 2D tra trig native 7048.25 83.00 500×500 4.0 1.56×1.56 320×320 3:42
TWIST 4D cor insp dynamic 1.80 0.68 500×500 5.0 1.95×1.95 256×256 0:37
VIBE
FatSat
3D cor insp post-contrast 3.35 1.18 500×500 4.0 0.98×0.98 512×512 0:33
VIBE
FatSat
3D tra insp post-contrast 3.35 1.18 400×350 4.0 0.78×0.78 512×448 0:32
TrueFISP 2D+t cor forced post-contrast 317.10 1.08 500×500 6.0 0.98×0.98 512×512 0:24
TrueFISP 2D+t sag R forced post-contrast 317.10 1.11 450×450 6.0 0.88×0.88 512×512 0:25
TrueFISP 2D+t sag L forced post-contrast 317.10 1.11 450×450 6.0 0.88×0.88 512×512 0:25
All sequences are acquired in 3D or 2D multi-slice modes and were accelerated using GRAPPA with a parallelization factor of 2. Breathing mode
indicates free breathing, one or more breath-hold in inspiration or expiration, expiration triggered acquisition or dynamic acquisition during forced in- and
expiration.
doi:10.1371/journal.pone.0137282.t002
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Small airway disease. Tree-in-bud appearance and peripheral bronchiectasis (visibility of
bronchi within 2 cm from the pleural surface): 0 = absent, 1 =50% of lobe, 2 =>50% of lobe.
Consolidations. Areas with an increase in parenchymal signal intensity> 2.0 cm in diam-
eter with possible presence of air bronchogram or contrast enhancement [13]: 0 = absent, 1 =
50% of lobe, 2 =>50% of lobe.
Nodules. 0 = absent, 1 =< 1.0 cm, 2 = 1.0 cm.
Parenchymal defects. Areas of decrease in parenchymal signal intensity on inspiratory
HASTE, VIBE, and/or post-contrast VIBE [14]: 0 = absent, 1 =50% of lobe, 2 =>50% of
lobe.
Perfusion defects. Areas of reduced or missing enhancement on subtracted peak perfu-
sion maps. Other causes not related to airway disease or emphysema, in particular pulmonary
embolism, infiltration and atelectasis, were excluded [13]: 0 = absent, 1 =50% of lobe, 2 =
>50% of lobe.
Perfusion defects due to collateral causes. Perfusion defects not related to airway disease
(infiltration, atelectasis, pulmonary embolism): 0 = absent, 1 =50% of lobe, 2 =>50% of
lobe.
Impaired respiratory mechanics. Motion impairment of the chest wall and/or diaphragm
such as diaphragmatic depression with / without paradoxical motion as published previously
[15–17]. Different causes, in particular phrenic paralysis or atelectasis were excluded. The eval-
uation was performed for each hemithorax: 0 = absent, 1 = moderate impairment (diaphrag-
matic flattening, reduced or paradoxical motion of chest wall and/or diaphragm), 2 = severe
impairment (diaphragmatic motion hardly visible).
Impairment of respiratory mechanics due to collateral causes. Respiratory motion
impairment as collateral finding (prevailing conditions which are not COPD-related, i.e.
phrenic paralysis or atelectasis): 0 = absent, 1 = moderate impairment, 2 = severe impairment.
Pulmonary trunk ectasia. 0 = diameter PA< 29 mm, 1 = diameter PA 29 mm [18].
Right ventricular enlargement. Right ventricle (RV) to left ventricle ratio (LV), 0 = RV/
LV 1.0, 1 = RV/LV> 1.0 [19].
Special findings. This category summarizes unspecific findings which are not met by
other categories, such as parenchyma bands, dystelectasis, pleural effusion, pleurisy, pneumo-
thorax, or pleural peels. Such special findings were analysed separately for the right and left
hemithorax: 0 = absent, 1 = present.
All 39 MRI datasets were evaluated in consensus by three chest radiologists with 2–4 years
of experience in pulmonary 1H-MRI. MRI2 was assessed one week after MRI1. Every single
observation was documented for further evaluation of test-retest reliability. Subscores were cal-
culated for each category as the sum of each lobar score, and the global score was calculated as
the sum of all category subscores. Image quality was rated in consensus for every single MRI
sequence: 0 = excellent, 1 = reduced but diagnostic, 2 = not diagnostic.
Statistical analysis
Scores are given as median with interquartile range (Q1 to Q3). The test-retest reliability
(MRI1 vs. MRI2) was assessed by weighted kappa with quadratic weighting [20] for ordinal
variables and by Cohen´s kappa [21] for nominal variables. We employed the following levels
of agreement: 0–0.20 = poor, 0.21–0.40 = fair, 0.41–0.60 = moderate, 0.61–0.80 = substantial,
0.81–1.00 = almost perfect [22]. Global sum scores and category subscores of test and retest
were compared by Wilcoxon signed-rank test for skewed distributions and paired Student's t-
test for normal distributions. Calculations were done using IBM SPSS statistics 22 (Interna-
tional Business Machines Corporation IBM, Armonk, NY, USA).
Test-Retest Reliability of Lung MRI in COPD
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Results
Technical feasibility and image quality
MRI1 could be completed in 18 of 20 patients, and partially completed in 2 of 20 patients who
refused intravenous contrast application. MRI2 was rejected by 1 patient, and again 2 patients
refused intravenous application of contrast media. The semiquantitative visual image evalua-
tion did not exceed 20 minutes per dataset. Inspiratory HASTE, free-breathing TrueFISP, as
well as dynamic TrueFISP during maximum inspiration and expiration demonstrated excellent
image quality (score = 0) at MRI1 and MRI2. Image quality of other MRI sequences was also
thoroughly reported as being diagnostic (score = 1) or excellent (score = 0) with few exceptions:
post-contrast VIBE showed insufficient image quality due to respiratory motion artifacts in 2
patients at MRI1 (1 in transversal, 1 in coronal plane) and 3 at MRI2 (2 transversal, 1 coronal).
The respiratory triggered BLADE showed insufficient image quality in 2 subjects at MRI2 (1
transversal, 1 coronal). The test-retest reliability of image quality scoring of MRI1 vs. MRI2
was moderate with ĸ = 0.41 (95%CI = 0.21–0.60), meaning that image quality may be some-
what variable within the same subject.
Test-retest reliability of MRI in COPD
The median global score for n = 19 patients was 10 (Q1: 8.00; Q3: 16.00) for MRI1 and 11 (Q1:
6.00; Q3: 15.00) for MRI2. The global scores and category subscores were not significantly dif-
ferent between MRI1 and MRI2 (subscore data not shown). We found an “almost perfect” test-
retest reliability of MRI1 vs. MRI2 (ĸ = 0.86, 95%CI = 0.81–0.91) (Table 3) based on the
entirety of single observations. Kappa statistics indicated “substantial” or “almost perfect”
agreement for MRI1 vs. MRI2 with regard to the majority of category subscores (ĸ = 0.64–1.00)
(Table 3). For special findings such as atelectasis or pleural effusion (ĸ = 0.42, 95%CI = 0.00–
0.93), the agreement for MRI1 vs. MRI2 was “moderate” (Table 3), for tracheal abnormalities
(ĸ = 0.21, 95%CI = 0.00–0.75) it was “fair”.
At single patient level, airway abnormalities (Fig 1), pulmonary consolidations, COPD
related-perfusion defects (Fig 2, Fig 3), and impairments of respiratory mechanics (collateral
findings) were detected in the same number of patients at MRI1 and MRI2 (Table 4). The
Table 3. Weighted kappa of test vs. retest (consensus of n = 3 readers), displayed for category sub-
scores and for the global score.
Category κ 95% CI
Tracheal disease 0.21 0.00–0.75
Bronchial disease 0.88 0.55–0.98
Small airway disease 1.00 1.00–1.00
Consolidations 0.80 0.55–1.00
Nodules 0.75 0.32–1.00
Parenchymal defects 0.77 0.49–1.00
Perfusion defects 0.77 0.61–0.93
Perfusion defects (collateral findings) 0.74 0.24–1.00
Impaired respiratory mechanics 0.76 0.45–1.00
Impaired respiratory mechanics (collateral findings) 1.00 1.00–1.00
Pulmonary trunk ectasia 0.86 0.17–1.00
Right ventricular enlargement 0.64 0.00–1.00
Special findings 0.42 0.00–0.93
Global 0.86 0.81–0.91
doi:10.1371/journal.pone.0137282.t003
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prevalence of pulmonary nodules was reported slightly higher at MRI1 (37%) than in MRI2
(26%), just as well as the prevalence of special findings (42% vs. 32%). Other categories differed
by 1 subject at most between MRI1 and MRI2 (Table 4).
The number of lung lobes with COPD-related findings was relatively stable for most catego-
ries fromMRI1 through MRI2, as well as their attributed score value (Table 5). Airway catego-
ries, consolidations, nodules, collateral perfusion defects, collateral impairments of respiratory
mechanics (Fig 4) and right ventricular enlargement showed similarly low prevalence of up
to 16% of lung lobes/chest compartments, mainly with low score values (score = 1) at both
timepoints (Table 5). A relatively high number of lung lobes/chest compartments showed
parenchymal defects (Fig 3) based on morphological MRI sequences (26% vs. 33%), perfusion
defects (83% vs. 84%) and impaired respiratory mechanics (39% vs. 45%) as well as pulmonary
trunk ectasia (26% vs. 21%) at both examinations (Table 5). In particular the number of paren-
chymal defects seemed to differ between both examinations, with a tendency towards a higher
detection rate of minor parenchymal defects at MRI2 (37 vs. 29 lobes), whereas the number of
large parenchymal defects remained stable.
Fig 1. Examples of of typical findings. (A) Saber sheath trachea in a 69 year old patient diagnosed with
GOLD stage IV (“tracheal disease”-score = 1). (B) Complete destruction of the middle lobe due to severe
bronchiectasis in a 59 year old patient with GOLD stage II (lobar score for “bronchial disease” = 2). (C) Small
airway disease (arrowhead) in the right lower lobe of a 50 year old patient with GOLD stage I (lobar score for
the category “small airway disease” = 1). (D) Bronchial carcinoma 1.0 cm in the right lower lobe adjacent to
the bronchovascular bundle of a 79 year old patient with GOLD stage IV (lobar score for the category
“nodules” = 2).
doi:10.1371/journal.pone.0137282.g001
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Discussion
The aim of the study was the assessment the test-retest reliability of a combined morpho-func-
tional MRI protocol based on commercially available sequences for COPD-related regional
abnormalities of lung structure, perfusion, and respiratory mechanics as well as pulmonary
hypertension. Continuously high image quality is a prerequisite for this concept, since insuffi-
cient or varying image quality decreases reproducibility with significant influence on image-
based quantitative or semiquantitative biomarkers. Many patients with severe COPD are short
of breath and thus unable to comply with long breath-holding times. Image quality is therefore
frequently limited. Gay et al. reported a maximum breath-holding time of 25 seconds during
CT imaging of patients with COPD, chronic heart failure or extensive smoking history and 45
seconds in patients without pulmonary disease [23]. To meet the requirements for scanning
COPD patients, the protocol employed respiratory triggered and free breathing sequences
which are less stressful for the patient and reduce or eliminate the influence of respiratory
motion. Breath-holding times of most sequences were below 25 seconds with few exceptions:
The 4D perfusion sequence (TWIST) covered a time period of 37 seconds since circulation
times are difficult to predict in morbid patients and frequently prolonged. However, observed
individual abilities of COPD patients to hold breath were sufficient for artifact-free perfusion
Fig 2. Discrepancy of parenchymal structure and function in mild COPD. 57 year old male patient
suffering frommild COPD (GOLD stage I). VIBE (A), post-contrast VIBE (B), as well as HASTE (C) did not
show significant parenchymal alterations. However, functional MRI with 4D first pass perfusion revealed
scattered minor defects (arrowheads) across the lung on subtracted images (D) and therefore was rated with
a perfusion score of 1 for each lobe.
doi:10.1371/journal.pone.0137282.g002
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acquisition during the first pulmonary passage of the contrast bolus (15–25s). The fat-saturated
VIBEs were the only morphological acquisitions exceeding breath-holding times of 25 seconds.
In general, the imaging protocol proved to be robust since image quality was at least diagnostic
at both examinations, with only few fat-saturated VIBEs and BLADE acquisitions in different
patients showing insufficient image quality. This may be partially due to the prolonged breath-
holding time of fat-saturated VIBE, but advances in parallel imaging will certainly allow for a
reduction of fat-saturated VIBE acquisition times in the near future. Although most MRI data
sets showed a high level of image quality, the test-retest reliability of image quality scoring of
MRI1 vs. MRI2 was only moderate with ĸ = 0.41. This reflects intra-subject fluctuations of
image quality related to image artifacts of insignificant extent, mainly minor respiratory
motion, cardiac motion, and in some cases, Gibbs ringing artifacts. Furthermore, the 4D DCE
perfusion sequence and the contrast regimen were also designed to meet the requirements of a
software-based calculation of regional quantitative perfusion parameters. The designed MRI
protocol also met the expectations concerning test-retest reliability, since COPD-related lung
abnormalities were depicted with “almost perfect” reproducibility within 1 day. For imaging-
based phenotyping of COPD, the extent of airway remodeling and pulmonary emphysema
Fig 3. Pulmonary emphysema with concomitant perfusion deficit.Grossly circumscribed structural
defect (arrowheads) located in the periphery of the right upper lobe of a 50 year old male patient with GOLD
stage I, as displayed on VIBE (A), post-contrast VIBE (B), and HASTE (C). A corresponding, but slightly
larger defect (arrowheads) is visible on subtraction images of MR perfusion datasets (D). With regard to the
category subscore “parenchymal defects”, the lobe was rated with a score of 1, and with regard to the
perfusion score, it was rated with a 2. Additionally, one recognizes a small pleural effusion in the right oblique
fissure which is also visible in Fig 4B.
doi:10.1371/journal.pone.0137282.g003
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would need to be systematically assessed [24]. Today, CT is the modality of choice for in vivo
imaging of the pulmonary parenchyma and airways in COPD [2,25]. MRI of the lung remains
challenging due to low proton density and thus lowMRI signal of lung tissue. Spatial resolution
of MRI is inferior to CT in the order of 2 to 4 times, thus affecting airway imaging which can
be performed down to the segmental level in healthy individuals. However, bronchial wall
thickening and dilatation increase visibility on MRI and improve the specificity of MRI for air-
way pathology. Furthermore, small airways disease with tree-in-bud pattern is also sensitively
depicted by MRI [6,26]. The present study is the first of its kind to systematically evaluate air-
way alterations in COPD patients with MRI. Airway pathologies were found in approximately
half of the patients in both MR examinations. However, the number of affected lung lobes was
infrequent at both time points. Kappa statistics indicated “almost perfect” reproducibility for
Table 4. Number of patients with COPD-relevant MRI findings in MRI1 and MRI2 ordered by catego-
ries. 2 individuals rejected contrast media at each examination.
Findings (Category) MRI1 MRI2
Tracheal disease 3/19 3/19
Bronchial disease 6/19 6/19
Small airway disease 4/19 4/19
Consolidations 6/19 6/19
Nodules 7/19 5/19
Parenchymal defects 9/19 10/19
Perfusion defects 16/17 16/17
Perfusion defects (collateral findings) 3/17 4/17
Impaired respiratory mechanics 8/19 9/19
Impaired respiratory mechanics (collateral findings) 2/19 2/19
Pulmonary trunk ectasia 5/19 4/19
Right ventricular overload 2/19 1/19
Special findings 8/19 6/19
doi:10.1371/journal.pone.0137282.t004
Table 5. Number of abnormal lung lobes or thoracic compartments as observed on MRI1 or MRI2, ordered by category and by score point (0, 1, or
2 points) for n = 19 patients (n = 114 lobes). Note that the total number of lung lobes for the category perfusion is reduced by 2 patients (12 lobes) who
rejected contrast media at each examination.
Number of rated lobes (∑ = 114) / or compartments
Pathology (Category) N score = 0 N score = 1 N score = 2 Compartment
MRI1 MRI2 MRI1 MRI2 MRI1 MRI2
Tracheal disease 16 16 3 3 0 0 Trachea / Stem
Bronchial disease 106 107 7 5 1 2 Lobe
Small airway disease 110 110 4 4 0 0 Lobe
Consolidations 108 107 5 5 1 2 Lobe
Nodules 104 106 8 6 2 2 Lobe
Parenchymal defects 84 76 29 37 1 1 Lobe
Perfusion defects (102 lobes) 17 16 49 46 36 40 Lobe
Perfusion defects (collateral findings, 102 lobes) 99 98 2 2 1 2 Lobe
Impaired respiratory mechanics 23 21 13 14 2 3 Chest r/l
Impaired respiratory mechanics (collateral findings) 36 36 2 2 0 0 Chest r/l
Pulmonary trunk ectasia 14 15 5 4 Pulm. trunk
Right ventricular enlargement 17 18 2 1 Heart
Special findings 29 32 9 6 Chest r/l
doi:10.1371/journal.pone.0137282.t005
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abnormalities of large and small airways. The evaluation of tracheal abnormalities showed a
“fair” agreement between MRI1 and MRI2, reflecting reduced test-retest reliability compared
to other subscore categories. This might be based on the fact that the evaluation of tracheal nar-
rowing was based on the combined evaluation of free-breathing, respiratory-triggered and
inspiratory breath-hold acquisitions which comes close to but obviously cannot replace
dynamic acquisitions during forced inspiration/expiration and free breathing. In patients with
COPD, the additional loss of signal due to emphysematous destruction, hyperinflation and
hypoxic pulmonary vasoconstriction deteriorates conditions for structural 1H-MRI [27,28]. In
the present study, parenchymal defects based on morphological MR images were detected in a
substantial number of lung lobes at both MRI1 and MRI2 (26% vs. 33%) with “substantial”
agreement between both examinations. Ley-Zaporozhan et al. compared MRI-based and CT-
based emphysema classification and reported that the extent of emphysema was rated correctly
using morphological MRI sequences in 63% of lung lobes, suggesting that emphysema charac-
terization with structural MRI is less sensitive than with CT, but provides a certain impression
of emphysema severity [14]. Moreover, the protocol was aimed to cover frequent COPD-
related inflammatory or potentially malignant comorbidities such as pneumonia and pulmo-
nary nodules, which should not be missed in cross-sectional imaging of the lung. These
Fig 4. Respiratory mechanics in mild and advanced COPD. Snapshots from dynamic TrueFISP in coronal
orientation showing respiratory mechanics in a 50 year old male patient with GOLD stage I (A, B) and a 77
year old male patient with GOLD stage III (C, D). Diaphragmatic function of the patient with mild COPD
appeared normal, as shown in inspiration (A) and expiration (B). Note a small pleural effusion in the right
oblique fissure as secondary finding (arrowhead). The patient with GOLD stage III showed bilateral phrenic
flattening and signs of whipsaw-motion in inspiration (C) and expiration (D). Phrenic motion amplitude was
bilaterally restricted, with hardly recognizable motion on the left side (category subscore for respiratory
mechanics right = 1; left = 2). Note an emphysemal bulla in the left upper lobe as additional finding.
doi:10.1371/journal.pone.0137282.g004
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findings had a low prevalence in our population but were depicted with high (“substantial”)
test-retest reproducibility. This is perfectly in keep with recently published results on lung nod-
ule detection in a lung cancer CT screening population by Sommer et al., who could show that
the inter-rater variability for lung nodules was only 84% with κ = 0.65 with a similar morpho-
logical protocol but without contrast application [29]. In COPD patients, perfusion can be
adversely affected by hypoxic pulmonary vasoconstriction, remodeling or rarefication of the
pulmonary vasculature due to tissue destruction [30]. MRI is capable of depicting such perfu-
sion abnormalities with similar sensitivity and specificity as pulmonary radionuclide scintigra-
phy [31]. Moreover, Ley-Zaporozhan et al. reported a high sensitivity of MR perfusion imaging
for emphysematous lung areas visible on CT [32]. However, contrast enhanced MR perfusion
has been shown to be an appropriate surrogate parameter for both, parenchymal destruction
and airway obstruction [33–35]. The 4D DCE perfusion study employed for the present study
demonstrated “substantial” test-retest reproducibility concerning the presence, localization
and extent of lung areas with reduced perfused blood volume. Additionally, it revealed a high
prevalence of lung areas with reduced blood content per volume at both timepoints (86% vs.
88%). It is well known that advanced hyperinflation and emphysema in COPD affect chest wall
and diaphragmatic motion [16,17] leading to reduced extent of motion and/or paradoxical
movement, which has been studied by 4DCT [36] as well as time-resolved MRI acquisitions
[15,17]. Image-based evaluation of respiratory mechanics is of potential value for patient moni-
toring in the context of interventions such as lung volume reduction surgery, which are
believed to improve lung function through respiratory mechanics [37]. However, the reproduc-
ibility of findings in dynamic TrueFISP during maximum inspiration and expiration has not
been assessed yet. Dynamic TrueFISP sequences during maximum inspiration and expiration
revealed respiratory motion impairment in the same number of chest compartments at MRI1
and MRI2 (each 17/38) with similar extent of severity. In this context, extensive motivation
and guidance of the patients ensured high test-retest reliability. Morphological indicators of
pulmonary hypertension were detected with high reproducibility, in detail right ventricular
enlargement and pulmonary trunk ectasia, thereby providing information on the probability of
severe exacerbations [38] and 5-year survival rate [39]. Pathologies addressed by the category
“special findings” (which entailed mainly small atelectasis and minor pleural effusion) are per
se highly variable throughout 24 hours. As a result, kappa statistics indicated moderate test-
retest reliability for this category, which should not be attributed to MRI. In the near future,
new MRI techniques based on near zero echo times such as ultra-short echo time (UTE)
sequences will improve image quality of proton MRI of the lung, providing higher spatial
resolution, better signal-to-noise ratio and shorter scan time [40, 41]. Most clinical scanner
vendors already offer UTE sequences for selected MRI devices, in many cases as work in prog-
ress (WIP) sequences. First experiences in subjects with cystic fibrosis [42] indicate the high
potential of these techniques in the evaluation of pulmonary structure and function in subjects
with lung diseases. The proposed imaging protocol will be the basis of a prospective study
(DRKS00005072) comparing the performance of MRI- with CT-based phenotyping of COPD
in a large multicenter subcohort of the German COPD cohort (Impact of Systemic Manifesta-
tions/Comorbidities on Clinical State, Prognosis, Utilisation of Health Care Resources in
Patients with COPD study “COSYCONET”, NCT01245933).
Conclusion
The proposed imaging protocol allowed for the evaluation of COPD-related alterations of
bronchi, pulmonary parenchyma, perfusion, and respiratory mechanics with high test-retest
reliability. Even in patients with advanced COPD, image quality of most acquisitions was at
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least diagnostic at both examinations. The proposed imaging protocol appears valuable for
phenotyping COPD as well as monitoring of regional lung structure and function in clinical
trials.
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